Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.

Brief summaries of recent medtech market and industry developments. This month we cover Edwards Lifescience's Sapien TAVI device, and news from emerging neurostimulation companies.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.